Hoffmann-la Roche Inc.

Arrowhead Madison, Inc.

Arrowhead Pharmaceuticals, Inc.

Basilea Pharmaceutica Ag

F. Hoffmann-la Roche Ag

Arrowhead Research Corporation

Peter Mohr

Michael J Klaus

Bernd Kuhn

Alfred Binggeli

Hans-Peter Maerki

Uwe Grether

Eric Argirios Kitas

Hans Peter Maerki

Benoit Hornsperger

David B Rozema

Johannes Aebi

Philipp Hadwiger

David L Lewis

Georges Hirth

Torsten Hoffmann

Darren H Wakefield

Hans Hilpert

Peter Loeliger

Rainer Eugen Martin

Jean Ackermann

Matthew Wright

Kurt E Amrein

Xuefei Tan

Jon Asher Wolff

Fabienne Ricklin

Andrei V Blokhin

Paul Hebeisen

Michael Rosenberger

Markus Rudolph

Philippe Pflieger

Wolfgang Guba

Hans Peter Wessel

Allen John Lovey

Matthias Heinrich Nettekoven

Henner Knust

Hans G Richter

Olivier Roche

Stephan Roever

Luca Claudio Gobbi

Michelangelo Scalone

Jean-Marc Plancher

Katrin Groebke Zbinden

Wolfgang Haap

Konrad H Bleicher

Alexander Mayweg

Luke Green

Ekkehard Weiss

Markus Meyer

Ingo Roehl

Michael Reutlinger

Hans Martin Mueller

Marc Muller

Kerstin Jahn-Hofmann

Guenther Ott

Pierre Barbier

Andreas Dominik Christ

Yongfu Liu

Jeffrey Carlson

Jonathan D Benson

Roberto Iacone

Alexander V Mayweg

Wolfgang Pirson

Franz Bauer

Linda Valis

Mingwei Zhou

Luke Gideon Granville Green

Christopher Self

Urs Schwitter

Markus Boehringer

Wilma Thuer

Sven Taylor

Beat Wirz

Hans Iding

Werner Bollag

Werner Mueller

Ulrike Obst

Roland Humm

Philippe Guerry

Paula Nanette Belloni

Olaf Grassmann

Tadakatsu Takahashi

Serena Maria Fantasia

Zhanguo Wang

Nicole Wyttenbach

Wenming Chen

Francesco Sinigaglia

Rudolf E Minder

Paola Panina-Bordignon

Ingo Röhl

Günther Ott

Torsten Hoffman

Erik Kitas

Kerstin Jahn-Hoffmann

Lukas Dreier

Karsten Faehnrich

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, R, R, R, Rand Rare as described herein, compositions including the compounds and methods of using the compounds.

Difluoroketamide derivatives as HtrA1 inhibitors

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, R, R, Rand Rare as described herein, compositions including the compounds and methods of using the compounds.

Trifluoromethylpropanamide derivatives as HTRA1 inhibitors

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, R, A, X and Rare as described herein, compositions including the compounds and methods of using the compounds.

Difluoroketamide derivatives as HTRA1 inhibitors

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, X, A and Rare as described herein, compositions including the compounds and methods of using the compounds.

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, Rand Rare as described herein, compositions including the compounds and methods of using the compounds.

Difluoroketamide derivatives

The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.

Compositions for targeted delivery of siRNA

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, Rand Rare as described herein, compositions including the compounds and methods of using the compounds.

Trifluoromethylpropanamide derivatives

The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.

Small molecule conjugates for intracellular delivery of biologically active compounds

The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.

Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

The invention provides novel compounds having the general formula (I) wherein R, R, Rand Rn are as described herein, compositions including the compounds and methods of using the compounds.

Imidazolylketone derivatives

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, R, R, R, R, R, A, AAand n are as described herein, compositions including the compounds and methods of using the compounds. The compounds of the present invention are useful as inhibitors of aldosterone synthase. The compounds may be used, for example, in the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

Bicyclic dihydroquinoline-2-one derivatives

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, A, Aand Aare as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

Dihydroquinoline-2-one derivatives

Growing community of inventors

Basel, Switzerland

Peter Mohr